Shanghai No1 Pharmacy Co Ltd (600833) - Net Assets
Based on the latest financial reports, Shanghai No1 Pharmacy Co Ltd (600833) has net assets worth CN¥1.19 Billion CNY (≈ $174.37 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.99 Billion ≈ $291.35 Million USD) and total liabilities (CN¥799.41 Million ≈ $116.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600833 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.19 Billion |
| % of Total Assets | 59.85% |
| Annual Growth Rate | 6.1% |
| 5-Year Change | 50.51% |
| 10-Year Change | 59.09% |
| Growth Volatility | 73.81 |
Shanghai No1 Pharmacy Co Ltd - Net Assets Trend (1994–2025)
This chart illustrates how Shanghai No1 Pharmacy Co Ltd's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Shanghai No1 Pharmacy Co Ltd to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai No1 Pharmacy Co Ltd (1994–2025)
The table below shows the annual net assets of Shanghai No1 Pharmacy Co Ltd from 1994 to 2025. For live valuation and market cap data, see Shanghai No1 Pharmacy Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.17 Billion ≈ $171.33 Million |
+2.31% |
| 2024-12-31 | CN¥1.14 Billion ≈ $167.46 Million |
+13.48% |
| 2023-12-31 | CN¥1.01 Billion ≈ $147.57 Million |
+5.19% |
| 2022-12-31 | CN¥958.68 Million ≈ $140.28 Million |
+23.24% |
| 2021-12-31 | CN¥777.92 Million ≈ $113.83 Million |
+3.82% |
| 2020-12-31 | CN¥749.32 Million ≈ $109.65 Million |
+2.32% |
| 2019-12-31 | CN¥732.34 Million ≈ $107.16 Million |
+9.37% |
| 2018-12-31 | CN¥669.57 Million ≈ $97.98 Million |
-6.23% |
| 2017-12-31 | CN¥714.07 Million ≈ $104.49 Million |
-2.98% |
| 2016-12-31 | CN¥736.00 Million ≈ $107.70 Million |
-6.01% |
| 2015-12-31 | CN¥783.09 Million ≈ $114.59 Million |
+20.30% |
| 2014-12-31 | CN¥650.97 Million ≈ $95.26 Million |
+21.42% |
| 2013-12-31 | CN¥536.14 Million ≈ $78.45 Million |
+7.26% |
| 2012-12-31 | CN¥499.84 Million ≈ $73.14 Million |
+16.40% |
| 2011-12-31 | CN¥429.41 Million ≈ $62.84 Million |
-1.48% |
| 2010-12-31 | CN¥435.88 Million ≈ $63.78 Million |
+8.36% |
| 2009-12-31 | CN¥402.25 Million ≈ $58.86 Million |
+28.04% |
| 2008-12-31 | CN¥314.16 Million ≈ $45.97 Million |
-20.17% |
| 2007-12-31 | CN¥393.54 Million ≈ $57.59 Million |
+60.13% |
| 2006-12-31 | CN¥245.77 Million ≈ $35.96 Million |
+5.63% |
| 2005-12-31 | CN¥232.68 Million ≈ $34.05 Million |
+14.83% |
| 2004-12-31 | CN¥202.62 Million ≈ $29.65 Million |
+6.93% |
| 2003-12-31 | CN¥189.49 Million ≈ $27.73 Million |
+7.48% |
| 2002-12-31 | CN¥176.31 Million ≈ $25.80 Million |
+6.52% |
| 2001-12-31 | CN¥165.52 Million ≈ $24.22 Million |
+141.35% |
| 2000-12-31 | CN¥-400.26 Million ≈ $-58.57 Million |
-43.83% |
| 1999-12-31 | CN¥-278.29 Million ≈ $-40.72 Million |
-378.36% |
| 1998-12-31 | CN¥99.97 Million ≈ $14.63 Million |
-71.05% |
| 1997-12-31 | CN¥345.33 Million ≈ $50.53 Million |
+13.10% |
| 1996-12-31 | CN¥305.33 Million ≈ $44.68 Million |
+6.17% |
| 1995-12-31 | CN¥287.59 Million ≈ $42.08 Million |
+54.00% |
| 1994-12-31 | CN¥186.74 Million ≈ $27.33 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai No1 Pharmacy Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1851.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥583.29 Million | 50.23% |
| Other Components | CN¥578.00 Million | 49.77% |
| Total Equity | CN¥1.16 Billion | 100.00% |
Shanghai No1 Pharmacy Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai No1 Pharmacy Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
STP&I Public Company Limited
BK:STPI
|
$316.33 Million |
|
Alucon Public Company Limited
BK:ALUCON
|
$316.43 Million |
|
Taiwan Optical Platform Co Ltd
TW:6464
|
$316.47 Million |
|
Regional Management Corp
NYSE:RM
|
$316.48 Million |
|
International CSRC Investment Holdings Co Ltd
TW:2104
|
$316.30 Million |
|
Sword Group S.E
F:9RS
|
$316.28 Million |
|
NEWRON PHARMACEUT. EO-20
F:NP5
|
$316.25 Million |
|
PARKEN Sport & Entertainment
CO:PARKEN
|
$316.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai No1 Pharmacy Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,135,612,000 to 1,161,285,666, a change of 25,673,666 (2.3%).
- Net income of 57,747,287 contributed positively to equity growth.
- Dividend payments of 50,791,649 reduced retained earnings.
- Other comprehensive income decreased equity by 290,697,238.
- Other factors increased equity by 309,415,265.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥57.75 Million | +4.97% |
| Dividends Paid | CN¥50.79 Million | -4.37% |
| Other Comprehensive Income | CN¥-290.70 Million | -25.03% |
| Other Changes | CN¥309.42 Million | +26.64% |
| Total Change | CN¥- | 2.26% |
Book Value vs Market Value Analysis
This analysis compares Shanghai No1 Pharmacy Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.96x to 1.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | CN¥0.81 | CN¥9.69 | x |
| 1995-12-31 | CN¥0.79 | CN¥9.69 | x |
| 1996-12-31 | CN¥0.87 | CN¥9.69 | x |
| 1997-12-31 | CN¥1.48 | CN¥9.69 | x |
| 1998-12-31 | CN¥-0.37 | CN¥9.69 | x |
| 1999-12-31 | CN¥-1.15 | CN¥9.69 | x |
| 2000-12-31 | CN¥-1.74 | CN¥9.69 | x |
| 2001-12-31 | CN¥0.72 | CN¥9.69 | x |
| 2002-12-31 | CN¥0.76 | CN¥9.69 | x |
| 2003-12-31 | CN¥0.82 | CN¥9.69 | x |
| 2004-12-31 | CN¥0.88 | CN¥9.69 | x |
| 2005-12-31 | CN¥1.01 | CN¥9.69 | x |
| 2006-12-31 | CN¥1.06 | CN¥9.69 | x |
| 2007-12-31 | CN¥1.82 | CN¥9.69 | x |
| 2008-12-31 | CN¥1.45 | CN¥9.69 | x |
| 2009-12-31 | CN¥1.80 | CN¥9.69 | x |
| 2010-12-31 | CN¥1.98 | CN¥9.69 | x |
| 2011-12-31 | CN¥1.84 | CN¥9.69 | x |
| 2012-12-31 | CN¥2.21 | CN¥9.69 | x |
| 2013-12-31 | CN¥2.32 | CN¥9.69 | x |
| 2014-12-31 | CN¥2.96 | CN¥9.69 | x |
| 2015-12-31 | CN¥3.39 | CN¥9.69 | x |
| 2016-12-31 | CN¥3.33 | CN¥9.69 | x |
| 2017-12-31 | CN¥3.09 | CN¥9.69 | x |
| 2018-12-31 | CN¥2.97 | CN¥9.69 | x |
| 2019-12-31 | CN¥3.28 | CN¥9.69 | x |
| 2020-12-31 | CN¥3.36 | CN¥9.69 | x |
| 2021-12-31 | CN¥3.43 | CN¥9.69 | x |
| 2022-12-31 | CN¥4.24 | CN¥9.69 | x |
| 2023-12-31 | CN¥4.49 | CN¥9.69 | x |
| 2024-12-31 | CN¥5.08 | CN¥9.69 | x |
| 2025-12-31 | CN¥5.21 | CN¥9.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai No1 Pharmacy Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.71%
- • Asset Turnover: 1.05x
- • Equity Multiplier: 1.74x
- Recent ROE (4.97%) is below the historical average (6.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 13.27% | 20.22% | 0.17x | 3.88x | CN¥6.11 Million |
| 1995 | 10.33% | 9.08% | 0.17x | 6.68x | CN¥606.20K |
| 1996 | 10.17% | 7.39% | 0.20x | 6.89x | CN¥347.50K |
| 1997 | -21.34% | -25.05% | 0.25x | 3.45x | CN¥-106.72 Million |
| 1998 | 0.00% | 0.00% | -0.05x | 0.00x | CN¥-265.55 Million |
| 1999 | 0.00% | 0.00% | -0.01x | 0.00x | CN¥-154.65 Million |
| 2000 | 0.00% | -3091.91% | 0.01x | 0.00x | CN¥-89.51 Million |
| 2001 | 13.46% | 8.46% | 0.55x | 2.92x | CN¥5.73 Million |
| 2002 | 7.20% | 2.66% | 1.00x | 2.71x | CN¥-4.94 Million |
| 2003 | 6.82% | 2.55% | 1.05x | 2.56x | CN¥-6.01 Million |
| 2004 | 6.49% | 2.41% | 1.27x | 2.12x | CN¥-7.10 Million |
| 2005 | 6.10% | 2.36% | 1.75x | 1.48x | CN¥-9.06 Million |
| 2006 | 5.30% | 2.15% | 1.25x | 1.96x | CN¥-11.52 Million |
| 2007 | 5.11% | 2.20% | 1.31x | 1.77x | CN¥-19.22 Million |
| 2008 | 6.38% | 2.08% | 1.64x | 1.88x | CN¥-11.34 Million |
| 2009 | 9.94% | 3.86% | 1.44x | 1.79x | CN¥-221.40K |
| 2010 | 7.07% | 2.64% | 1.46x | 1.84x | CN¥-12.56 Million |
| 2011 | 8.70% | 2.90% | 1.60x | 1.88x | CN¥-5.49 Million |
| 2012 | 7.39% | 2.68% | 1.52x | 1.81x | CN¥-12.85 Million |
| 2013 | 6.48% | 2.54% | 1.47x | 1.73x | CN¥-18.65 Million |
| 2014 | 5.75% | 2.62% | 1.31x | 1.68x | CN¥-27.37 Million |
| 2015 | 5.30% | 2.76% | 1.21x | 1.59x | CN¥-36.44 Million |
| 2016 | 6.31% | 3.03% | 1.28x | 1.63x | CN¥-26.86 Million |
| 2017 | 6.15% | 2.79% | 1.37x | 1.61x | CN¥-27.23 Million |
| 2018 | 7.12% | 4.01% | 1.09x | 1.63x | CN¥-19.07 Million |
| 2019 | 7.32% | 4.27% | 1.02x | 1.68x | CN¥-19.44 Million |
| 2020 | 9.23% | 4.32% | 1.14x | 1.88x | CN¥-5.69 Million |
| 2021 | 6.41% | 3.53% | 1.05x | 1.73x | CN¥-27.67 Million |
| 2022 | 15.08% | 5.41% | 1.30x | 2.14x | CN¥48.39 Million |
| 2023 | 8.91% | 4.91% | 0.98x | 1.86x | CN¥-10.87 Million |
| 2024 | 14.36% | 8.51% | 0.97x | 1.74x | CN¥49.50 Million |
| 2025 | 4.97% | 2.71% | 1.05x | 1.74x | CN¥-58.38 Million |
Industry Comparison
This section compares Shanghai No1 Pharmacy Co Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $1,949,303,857
- Average return on equity (ROE) among peers: 8.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai No1 Pharmacy Co Ltd (600833) | CN¥1.19 Billion | 13.27% | 0.67x | $316.33 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $1.30 Billion | 9.99% | 1.14x | $535.28 Million |
| Yunnan Hongxiang Yixintang (002727) | $810.77 Million | 22.52% | 0.88x | $917.76 Million |
| Luyan Pharma Co Ltd (002788) | $1.57 Billion | 8.34% | 2.28x | $621.39 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.27 Billion | 10.12% | 2.47x | $777.53 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.59 Billion | -15.22% | 2.98x | $278.33 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $2.16 Billion | 8.85% | 1.54x | $900.84 Million |
| Dashenlin Pharm Grp Co Ltd (603233) | $4.33 Billion | 16.22% | 1.00x | $2.69 Billion |
| Laobaixing Pharmacy (603883) | $3.87 Billion | 13.13% | 1.56x | $1.31 Billion |
About Shanghai No1 Pharmacy Co Ltd
Shanghai No.1 Pharmacy Co.,Ltd., together with its subsidiaries, engages in the retail and wholesale of pharmaceutical products in China. It sells food, medical equipment, health convenience products, and other commodities. The company serves medical institutions, pharmacies, commodity distribution companies, and franchise stores. Shanghai No. 1 Pharmacy Co.,Ltd. was founded in 1992 and is headqu… Read more